Navigation Links
Amarin Announces Financial Results for Fourth Quarter and Full Year 2007
Date:5/19/2008

er-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; general changes in International Financial Reporting Standards; and growth in costs and expenses. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Form 20-F for the fiscal year ended December 31, 2007, filed with the SEC on May 19, 2008.

Amarin Corporation plc

Period Ended 31 December 2007 (IFRS - UNAUDITED)

Selected Income Statement Data

Three months Twelve months

ended ended

31 31

December December

2007 2006 2007 2006

Total Total Total Total

$'000 $'000 $'000 $'000

Revenue - 400 - 500

Gross profit - 400 - 500

Operating expenses:

Research and development 1,748 3,925 10,772 14,380

Selling, General &

Administrative 3,222 2,516 14,109 11,311

Amortization of intangible

assets - 170 169 676

Impairment of intangible

fixed assets (non-cash) - - 8,784 -

Reorganization costs 1,898 1,898 -

Share-based compensa
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amarin Secures Global Intellectual Property Rights for Lipid Programs
2. Amarin Appoints Dr. William Mason as Lead Independent Director
3. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
4. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
5. Amarin Signs Agreement to Acquire Ester Neurosciences
6. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
7. Amarin Announces Initiation of Cardiovascular Development Strategy
8. Amarin to Present at 4th Annual Bio Investor Forum
9. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
10. Volcano Announces Acquisition of Novelis, Inc.
11. RainDance Announces Company Relocation and Manufacturing Startup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... HONG KONG , June 2, 2015 /PRNewswire/ -- China Cord ... "us" and "our"), China,s leading provider ... and stem cell storage services, today announced that the Special ... has appointed Houlihan Lokey ( China ... Steen & Hamilton LLP as its United ...
(Date:6/2/2015)... 2015 MGB Biopharma at ... problem  MGB Biopharma, a biopharmaceutical company ... address the major global problem of antibiotic resistance ... intravenous (IV) formulation of MGB-BP-3, designed for the treatment ... The intravenous formulation of MGB-BP-3 is currently ...
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... GenomeDx Biosciences today announced that ... classified various subtypes of bladder cancer based ... including one type associated with resistance to ... has potential as a tool to predict ... with muscle-invasive bladder cancers (MIBC). The study ...
Breaking Biology Technology:China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4
... Dec. 8 Kaiser Permanente Chairman and Chief,Executive ... today,at the World Healthcare Innovation and Technology conference ... Healthcare: Groundbreaking Innovations and,their Impact on Healthcare Delivery," ... care system where data and connectivity enable patient-centered ...
... SUNNYVALE, Calif., Dec. 8 Accuray Incorporated,(Nasdaq: ... field of radiosurgery, announced today,that 150 CyberKnife(R) Robotic ... milestone was achieved when Hospital Corporation of America,(HCA), ... System in,collaboration with consultant clinician partners at The ...
... (Amex: ETC ) ("ETC" or the "Company") ... BARA-MED(R)XD Monoplace hyperbaric oxygen chambers in the St. John ... chambers are the first computer-controlled hyperbaric chambers to be ... , Hyperbaric oxygen (HBO) chambers offer ...
Cached Biology Technology:Kaiser Permanente CEO Calls for 'Connected' Health Care 2Kaiser Permanente CEO Calls for 'Connected' Health Care 3Accuray Achieves Milestone of 150th CyberKnife System Installed Worldwide 2Accuray Achieves Milestone of 150th CyberKnife System Installed Worldwide 3Accuray Achieves Milestone of 150th CyberKnife System Installed Worldwide 4Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 2Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 3Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma 4
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... increased plant respiration in response to higher global temperatures ... into account plants' ability to adjust to changing conditions, ... In a Perspectives paper published April 28 by Science, ... suggesting that about 9 percent more carbon will be ...
... cabbage-eating moth may one day provide a safer, target-specific alternative ... They compared the ability of the four best-characterized jumping genes, ... produce a desired change, such as making the cell resistant ... transposon was five to 10 times better than the other ...
... at the University of California, Los Angeles have defined ... in almost a third of breast cancer survivors, according ... Clinical Cancer Research. , The key ... systems. , "These studies identify a biological basis ...
Cached Biology News:Plants' role in global warming re-examined 2Jumping gene could provide non-viral alternative for gene therapy 2Jumping gene could provide non-viral alternative for gene therapy 3Inflammation markers identify fatigue in breast cancer survivors 2
Recognizes the ~115 kDa NMDA receptor NR1 subunit in rat cortex tissue extracts....
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
... IV Recognizes an epitope located ... β-tubulin isotype IV. No reactivity ... observed. ascites fluid synthetic peptide ... of β-tubulin isotype IV, conjugated ...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Biology Products: